Medical Education Library

BEST PRACTICES IN: Extended-Regimen Oral Contraception:Modifying the Hormone-Free Interval


A supplement to Ob.Gyn. News. This supplement was sponsored by TEVA Women's Health.

Faculty/Faculty Disclosure

To view the supplement, click the image above.


• History of the Hormone-Free Interval
• Physiologic Effects of a Modified Hormone-Free Interval
• Safety and Efficacy of Extended-Regimen Oral Contraception

Faculty/Faculty Disclosure

David J. Portman, MD
Director and Principal Investigator
Columbus Center for Women's
Health Research
Columbus, Ohio
Dr. Portman is a consultant to Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, and TEVA Women's Health. He has received funding for clinical grants from Bayer, Boehringer Ingelheim, Depomed, Inc., Pfizer Inc., TEVA Women's Health, and Warner Chilcott.

Next Article: